Advertisement

Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis

Published:January 22, 2019DOI:https://doi.org/10.1016/j.jns.2019.01.036

      Highlights

      • Patients with multiple sclerosis had mean of 0.51 relapses/year before fingolimod.
      • Relapse rates decreased by >50% in each year of 3-year post-initiation period.
      • Median time on treatment was 33 months among patients initiating fingolimod.

      Abstract

      Objective

      To assess real-world durability of reduction in relapse rates among patients with multiple sclerosis (MS) receiving fingolimod therapy over a longer-term period of follow-up.

      Methods

      Patients with MS who initiated fingolimod were identified from a US claims database (January 1, 2009 to September 30, 2016) and followed for 3 years post-initiation. Annualized relapse rates (ARRs) were calculated during the 1-year pre-initiation period, and during each year over the 3-year follow-up period. Time from fingolimod initiation to discontinuation (≥60-day treatment gap) was also summarized.

      Results

      Among 1599 fingolimod initiators, 1158 (72%) had continuous fingolimod use up to the start of year 2 and 937 (59%) had continuous fingolimod use up to the start of year 3. The mean baseline ARR during the 1-year pre-initiation period for all initiators was 0.51. After fingolimod initiation, mean ARRs were consistently lower in each year of follow-up: 0.25 (95% CI: 0.22, 0.28) in year 1 for all fingolimod initiators, 0.22 (0.18, 0.25) in year 2 for patients with continuous fingolimod use up to the start of year 2, and 0.23 (0.19, 0.27) in year 3 for patients with continuous fingolimod use up to the start of year 3. Median time on treatment was 33 months for all patients initiating fingolimod.

      Conclusions

      Patients with MS who received continuous fingolimod therapy experienced a sustained reduction in relapse rates (>50% vs. baseline) during each year of a 3-year follow-up period.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Society NMS. MS Prevalence (Available from: http://www.nationalmssociety.org/About-the-Society/MS-Prevalence#)

        • Langer-Gould A.
        • Popat R.A.
        • Huang S.M.
        • Cobb K.
        • Fontoura P.
        • Gould M.K.
        • et al.
        Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.
        Arch. Neurol. 2006; 63: 1686-1691
        • Confavreux C.
        • Vukusic S.
        • Moreau T.
        • Adeleine P.
        Relapses and progression of disability in multiple sclerosis.
        N. Engl. J. Med. 2000; 343: 1430-1438
        • Pittock S.J.
        • McClelland R.L.
        • Mayr W.T.
        • Jorgensen N.W.
        • Weinshenker B.G.
        • Noseworthy J.
        • et al.
        Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.
        Ann. Neurol. 2004; 56: 303-306
        • Chung H.
        • Pharm B.
        • Miller A.
        All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
        in: ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008 Evaluation of Health Plan Member Use of an Online Prescription Drug Price Comparison Tool Payer Costs for Inpatient Treatment of Pathologic. 16(9). 2010: 703-712
        • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group
        Neurology. 1993; 43: 655-661
        • Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
        Lancet. 1998; 352: 1498-1504
        • Johnson K.P.
        • Brooks B.R.
        • Cohen J.A.
        • Ford C.C.
        • Goldstein J.
        • Lisak R.P.
        • et al.
        Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group.
        Neurology. 1995; 45: 1268-1276
        • Polman C.H.
        • O'Connor P.W.
        • Havrdova E.
        • Hutchinson M.
        • Kappos L.
        • Miller D.H.
        • et al.
        A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
        N. Engl. J. Med. 2006; 354: 899-910
        • Rudick R.A.
        • Cutter G.R.
        • Baier M.
        • Weinstock-Guttman B.
        • Mass M.K.
        • Fisher E.
        • et al.
        Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.
        Mult. Scler. 2005; 11: 626-634
        • Freedman M.S.
        Long-term follow-up of clinical trials of multiple sclerosis therapies.
        Neurology. 2011; 76: S26-S34
      2. FDA. FDA approves first oral drug to reduce MS relapses 2010 [Available from: (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm)

        • Kappos L.
        • Radue E.W.
        • O'Connor P.
        • Polman C.
        • Hohlfeld R.
        • Calabresi P.
        • et al.
        A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
        N. Engl. J. Med. 2010; 362: 387-401
        • Calabresi P.A.
        • Radue E.W.
        • Goodin D.
        • Jeffery D.
        • Rammohan K.W.
        • Reder A.T.
        • et al.
        Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Neurol. 2014; 13: 545-556
        • Cohen J.A.
        • Barkhof F.
        • Comi G.
        • Hartung H.P.
        • Khatri B.O.
        • Montalban X.
        • et al.
        Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
        N. Engl. J. Med. 2010; 362: 402-415
        • Fox E.
        • Edwards K.
        • Burch G.
        • Wynn D.R.
        • LaGanke C.
        • Crayton H.
        • et al.
        Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
        Mult Scler Relat Disord. 2014; 3: 607-619
        • Kappos L.
        • O'Connor P.
        • Radue E.W.
        • Polman C.
        • Hohlfeld R.
        • Selmaj K.
        • et al.
        Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
        Neurology. 2015; 84: 1582-1591
        • Cohen J.A.
        • Khatri B.
        • Barkhof F.
        • Comi G.
        • Hartung H.P.
        • Montalban X.
        • et al.
        Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
        J. Neurol. Neurosurg. Psychiatry. 2016; 87: 468-475
        • Bergvall N.
        • Makin C.
        • Lahoz R.
        • Agashivala N.
        • Pradhan A.
        • Capkun G.
        • et al.
        Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
        Curr. Med. Res. Opin. 2013; 29: 1647-1656
        • Bergvall N.
        • Makin C.
        • Lahoz R.
        • Agashivala N.
        • Pradhan A.
        • Capkun G.
        • et al.
        Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
        PLoS One. 2014; 9e88472
        • Boster A.
        • Nicholas J.
        • Wu N.
        • Yeh W.S.
        • Fay M.
        • Edwards M.
        • et al.
        Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database.
        Neurol Ther. 2017; 6: 91-102
        • Izquierdo G.
        • Damas F.
        • Paramo M.D.
        • Ruiz-Pena J.L.
        • Navarro G.
        The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study.
        PLoS One. 2017; 12e0176174
        • Braune S.
        • Lang M.
        • Bergmann A.
        • NeuroTransData Study G
        Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
        J. Neurol. 2016; 263: 327-333
        • He A.
        • Spelman T.
        • Jokubaitis V.
        • Havrdova E.
        • Horakova D.
        • Trojano M.
        • et al.
        Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
        JAMA Neurol. 2015; 72: 405-413
        • Ziemssen T.
        • Albrecht H.
        • Haas J.
        • Klotz L.
        • Lang M.
        • Lassek C.
        • et al.
        5 years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in Germany (P6.345).
        Neurology. 2017; 88 (P6.345)
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • Fong A.
        • Burnand B.
        • Luthi J.C.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med. Care. 2005; 43: 1130-1139
        • Ollendorf D.A.
        • Jilinskaia E.
        • Oleen-Burkey M.
        Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population.
        J Manag Care Pharm. JMCP. 2002; 8: 469-476
        • Chastek B.J.
        • Oleen-Burkey M.
        • Lopez-Bresnahan M.V.
        Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims.
        J. Med. Econ. 2010; 13: 618-625
        • Goel M.K.
        • Khanna P.
        • Kishore J.
        Understanding survival analysis: Kaplan-Meier estimate.
        Int J Ayurveda Res. 2010; 1: 274-278
        • Agashivala N.
        • Wu N.
        • Abouzaid S.
        • Wu Y.
        • Kim E.
        • Boulanger L.
        • et al.
        Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
        BMC Neurol. 2013; 13: 138
        • Lattanzi S.
        • Danni M.
        • Taffi R.
        • Cerqua R.
        • Carlini G.
        • Pulcini A.
        • et al.
        Persistence to oral disease-modifying therapies in multiple sclerosis patients.
        J. Neurol. 2017; 264: 2325-2329
        • Bergvall N.
        • Petrilla A.A.
        • Karkare S.U.
        • Lahoz R.
        • Agashivala N.
        • Pradhan A.
        • et al.
        Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
        J. Med. Econ. 2014; 17: 696-707
        • Starner C.I.
        • Alexander G.C.
        • Bowen K.
        • Qiu Y.
        • Wickersham P.J.
        • Gleason P.P.
        Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.
        Health Aff (Millwood). 2014; 33: 1761-1769
        • Patti F.
        Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.
        Patient Prefer Adherence. 2010; 4: 1-9
        • Bandari D.S.
        • Sternaman D.
        • Chan T.
        • Prostko C.R.
        • Sapir T.
        Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.
        J Manag Care Pharm JMCP. 2012; 18: 1-17
        • Wicks P.
        • Brandes D.
        • Park J.
        • Liakhovitski D.
        • Koudinova T.
        • Sasane R.
        Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients.
        Interact J Med Res. 2015; 4e6
        • Berchick E.R.
        • Hood E.
        • Barnett J.C.
        Health Insurance Coverage in the United States.
        2017 (Available from https://www.census.gov/content/dam/Census/library/publications/2018/demo/p60-264.pdf)